Cord blood stem cells aim to tame COVID-19 lung crisis

NCT ID NCT04565665

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether infusions of cord blood stem cells can help people with moderate to critical COVID-19 pneumonia. The trial includes 65 adults with COVID-19-related acute respiratory distress syndrome (ARDS). Researchers will compare stem cell treatment plus standard care against standard care alone to see if it improves survival and reduces the need for ventilators.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cord blood derived mesenchymal stem cells
What this could lead to
If it works, this could point toward a new treatment for severe COVID-19 pneumonia that reduces the need for ventilators and improves survival.
What could go wrong
This is an early phase 1/2 trial with only 65 participants, so results may not apply broadly. Stem cell infusions carry risks of infusion reactions or other serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.